Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Genome-wide association and Mendelian randomization analysis prioritizes bioactive metabolites with putative causal effects on common diseases

Youwen Qin, Guillaume Méric, Tao Long, Jeramie D. Watrous, Stephen Burgess, Aki S. Havulinna, View ORCID ProfileScott C. Ritchie, Marta Brożyńska, Pekka Jousilahti, Markus Perola, Leo Lahti, Teemu Niiranen, Susan Cheng, Veikko Salomaa, Mohit Jain, Michael Inouye
doi: https://doi.org/10.1101/2020.08.01.20166413
Youwen Qin
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
2School of BioSciences, University of Melbourne, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillaume Méric
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
3Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria 3004, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tao Long
4Bioinformatics and Structural Biology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
5Departments of Medicine and Pharmacology, University of California, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeramie D. Watrous
5Departments of Medicine and Pharmacology, University of California, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Burgess
6MRC Biostatistics Unit, Institute of Public Health, University of Cambridge, Cambridge
7British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aki S. Havulinna
8Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott C. Ritchie
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
9Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
10British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
11National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Scott C. Ritchie
Marta Brożyńska
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pekka Jousilahti
8Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Perola
8Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo Lahti
12Department of Future Technologies, University of Turku, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teemu Niiranen
8Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
12Department of Future Technologies, University of Turku, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Cheng
13Division of Cardiology, Brigham and Women’s Hospital, Boston, USA
14Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veikko Salomaa
8Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohit Jain
5Departments of Medicine and Pharmacology, University of California, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Inouye
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
2School of BioSciences, University of Melbourne, Melbourne, Victoria, Australia
7British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
9Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
10British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
11National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
15Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
16The Alan Turing Institute, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: minouye{at}baker.edu.au mi336{at}medschl.cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Bioactive metabolites are central to numerous pathways and disease pathophysiology, yet many bioactive metabolites are still uncharacterized. Here, we quantified bioactive metabolites using untargeted LC-MS plasma metabolomics in two large cohorts (combined N≈9,300) and utilized genome-wide association analysis and Mendelian randomization to uncover genetic loci with roles in bioactive metabolism and prioritize metabolite features for more in-depth characterization. We identified 118 loci associated with levels of 2,319 distinct metabolite features which replicated across cohorts and reached study-wide significance in meta-analysis. Of these loci, 39 were previously not known to be associated with blood metabolites. Loci harboring SLCO1B1 and UGT1A were highly pleiotropic, accounting for >40% of all associations. Two-sample Mendelian randomization found 46 causal effects of 31 metabolite features on at least one of five common diseases. Of these, 15, including leukotriene D4, had protective effects on both coronary heart disease and primary sclerosing cholangitis. We further assessed the association between baseline metabolite features and incident coronary heart disease using 16 years of follow-up health records. This study characterizes the genetic landscape of bioactive metabolite features and their putative causal effects on disease.

Competing Interest Statement

VS has received honoraria from Novo Nordisk and Sanofi for consultations. He also has ongoing research collaboration with Bayer Ltd (all unrelated to the present study).

Funding Statement

The FINRISK02 cohort was mainly funded by budgetary funds of the Finnish Institute for Health and Welfare. Important additional funding has been obtained from the Finnish Academy and domestic non-profit foundations. SCR was funded by the UK National Institute for Health Research (NIHR) (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust). LL is supported by the Academy of Finland (grant no 295741). TN is supported by the Academy of Finland (grant no 321351), the Finnish Medical Foundation, the Paavo Nurmi Foundation, and the Emil Aaltonen Foundation. VS has been supported by the Finnish Foundation for Cardiovascular Research. MI was supported by the Munz Chair of Cardiovascular Prediction and Prevention. This study was supported by the Victorian Government Operational Infrastructure Support (OIS) program. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this manuscript are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The FINRISK 2002 survey has been approved by the Ethical Committee on Epidemiology and Public Health of the Helsinki and Uusimaa Hospital District (decision number 87/2001) and the participants have provided an informed consent. The study is conducted according to the World Medical Association Declaration of Helsinki on ethical principles. The FHS study data was accessed via dbGaP (approved study 2014.2023).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data used in this study is available with an approved study proposal via the THL Biobank (FINRISK) and NIH dbGaP (Framingham Heart Study).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted August 04, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Genome-wide association and Mendelian randomization analysis prioritizes bioactive metabolites with putative causal effects on common diseases
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Genome-wide association and Mendelian randomization analysis prioritizes bioactive metabolites with putative causal effects on common diseases
Youwen Qin, Guillaume Méric, Tao Long, Jeramie D. Watrous, Stephen Burgess, Aki S. Havulinna, Scott C. Ritchie, Marta Brożyńska, Pekka Jousilahti, Markus Perola, Leo Lahti, Teemu Niiranen, Susan Cheng, Veikko Salomaa, Mohit Jain, Michael Inouye
medRxiv 2020.08.01.20166413; doi: https://doi.org/10.1101/2020.08.01.20166413
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Genome-wide association and Mendelian randomization analysis prioritizes bioactive metabolites with putative causal effects on common diseases
Youwen Qin, Guillaume Méric, Tao Long, Jeramie D. Watrous, Stephen Burgess, Aki S. Havulinna, Scott C. Ritchie, Marta Brożyńska, Pekka Jousilahti, Markus Perola, Leo Lahti, Teemu Niiranen, Susan Cheng, Veikko Salomaa, Mohit Jain, Michael Inouye
medRxiv 2020.08.01.20166413; doi: https://doi.org/10.1101/2020.08.01.20166413

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13403)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5182)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4225)
  • Public and Global Health (7526)
  • Radiology and Imaging (1717)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (73)
  • Transplantation (237)
  • Urology (206)